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Abstract
Background: Some studies but not others suggest angiotensin converting enzyme inhibitor (ACEi) or angiotensin
receptor blocker (ARB) use prior to major surgery associates with a higher risk of postoperative acute kidney injury
(AKI) and death.
Methods: We conducted a large population-based retrospective cohort study of patients aged 66 years or older who
received major elective surgery in 118 hospitals in Ontario, Canada from 1995 to 2010 (n=237,208). We grouped the
cohort into ACEi/ARB users (n=101,494) and non-users (n=135,714) according to whether the patient filled at least
one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. Our study outcomes were acute kidney
injury treated with dialysis (AKI-D) within 14 days of surgery and all-cause mortality within 90 days of surgery.
Results: After adjusting for potential confounders, preoperative ACEi/ARB use versus non-use was associated with 17%
lower risk of post-operative AKI-D (adjusted relative risk (RR): 0.83; 95% confidence interval (CI): 0.71 to 0.98) and 9%
lower risk of all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95). Propensity score matched analyses provided
similar results. The association between ACEi/ARB and AKI-D was significantly modified by the presence of preoperative
chronic kidney disease (CKD) (P value for interaction<0.001) with the observed association evident only in patients with
CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 0.78 versus No CKD: adjusted RR: 1.00; 95% CI: 0.81 to 1.24).
Conclusions: In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D,
and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to
inform optimal ACEi/ARB use in the peri-operative setting.
Keywords: Acute dialysis, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Major elective surgery
Background
Acute kidney injury (AKI) is a serious complication of
major surgery and severe AKI requires treatment with
acute dialysis [1,2]. Annually 230 million patients undergo
major surgery worldwide and around one million major
surgeries are complicated by AKI treated with dialysis
(AKI-D) [1-4]. The development of AKI is associated with
increased morbidity, mortality, and health care expendi-
tures [5]. A patient’s risk for developing postoperative AKI
is influenced by a variety of clinical factors including pre-
existing comorbidities (e.g. chronic kidney disease (CKD),
congestive heart failure, coronary artery disease, diabetes,
hypertension), clinical factors around the time of surgery
(e.g. volume depletion, blood loss, hypotension, adminis-
tration of vasoconstrictors), type of surgery (e.g. cardiac,
vascular), and certain medications used in the periopera-
tive period (e.g. antihypertensive medications) [2,3,6-10].
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given the possibility of modification prior to planned elect-
ive surgeries.
Angiotensin converting enzyme inhibitor (ACEi) and
angiotensin receptor blocker (ARB) are frequently pre-
scribed medications [11,12]. Despite their demonstrated
benefits in outpatient settings, their continued use in the
perioperative period remains controversial as preoperative
ACEi/ARB use may lead to the development of periopera-
tive hypotension and subsequent AKI [8,13-16]. However,
previous observational studies on the association between
preoperative ACEi/ARB use and AKI have had conflicting
results, and have focused on milder forms of AKI rather
than the most serious renal outcome of AKI-D. We con-
ducted this large retrospective cohort study to test the hy-
pothesis that preoperative ACEi/ARB use compared to
non-use associates with a different risk of AKI-D following
major elective surgery.
Methods
Setting and study overview
We conducted a retrospective, population-based cohort
study of patients aged 66 years or older admitted to a
hospital for a major elective surgery from 1995 to 2010
in Ontario, Canada. Ontario residents have universal ac-
cess to hospital care and physician services and those
aged 65 years or older have universal prescription drug
coverage [17]. We performed this study according to a
prespecified protocol approved by the research ethics
board at Sunnybrook Health Sciences Centre, Toronto,
Canada. The board deemed that patient informed con-
sent was not required for this study which used datasets
without patient identifiers. The reporting of this study
follows guidelines set out for observational studies (de-
tailed in Additional file 1) [18].
Data sources
We used linked large health care databases including
hospital discharge, physician billing, and prescription
drug claims databases to determine patients’ characteris-
tics, information on comorbidities, outcome data, and
drug usage. The Canadian Institute for Health Informa-
tion Discharge Abstract Database (CIHI-DAD) provides
detailed diagnostic and procedural information on all
hospitalizations. The Ontario Health Insurance Plan
(OHIP) database records all health claims for inpatient
and outpatient physician services. The Ontario Regis-
tered Persons Database (RPDB) records demographic
and vital status information. The Ontario Drug Benefits
(ODB) database provides highly accurate information
on dispensed outpatient medications [17]. These data-
bases have been used extensively to research health out-
comes and health services, including drug-induced and
perioperative AKI [3,19-23].
Study population
We included patients aged 66 years or older admitted to a
hospital for elective surgery between January 1, 1995 and
November 30, 2010. We excluded patients in their first
year of universal drug coverage (patients aged 65 years) to
avoid incomplete historical medication data. We included
five surgical categories: cardiac, vascular, thoracic, abdom-
inal, and retro-peritoneal, which all carry an appreciable
risk for AKI-D (sample database codes in Additional file
1) [2,3,6,7,22]. To avoid selecting emergent or urgent sur-
gery, we excluded all surgeries done during the course of a
non-surgical hospital admission. We also excluded hos-
pital admissions associated with missing or invalid identifi-
cation, or demographic information. To ensure all patients
had a recent access to health-care services, we limited our
analyses to patients with at least one dispensed outpatient
medication prescription in the 120 days prior to surgery.
We excluded patients with end-stage renal disease
(ESRD) prior to their surgery (i.e. any evidence of dialy-
sis or kidney transplantation) as the assessment of AKI-
D is different and may no longer be relevant. To avoid
the need to account for less frequently prescribed anti-
hypertensive medications in the analyses, we only consid-
ered patients with either no evidence of anti-hypertensive
medication use, or evidence of a prescription for the follow-
ing frequently prescribed anti-hypertensive medications in
the 120 days prior to surgery: ACEi, ARB, β-blocker, cal-
cium channel blocker, non-potassium sparing diuretic (loop
diuretic or thiazide diuretic). For patients with multiple eli-
g i b l es u r g e r i e sd u r i n gt h es t u d yp e r i o d ,w er a n d o m l ys e -
lected one surgical procedure to avoid within patient
clustering in the analyses.
Preoperative ACEi/ARB use
We grouped selected surgical cohort into ACEi/ARB
users and non-users according to whether the patient
filled at least one prescription for an ACEi or ARB (or
not) in the 120 days prior to surgery. We selected a time
frame of 120 days because the provincial drug plan re-
quires each prescription to be renewed at least once every
100 days and 20 extra days were considered to accommo-
date any missed doses resulting in a longer period between
renewal [24].
Baseline characteristics
We assessed demographic characteristics and comorbidities
using validated database codes whenever possible (detailed
in Additional file 1) [25-32]. We also determined concomi-
tant medication use in the 120 days prior to surgery.
Primary and secondary outcomes
Our primary outcome was AKI-D within 14 days of sur-
gery. AKI-D was determined using a set of high perform-
ance service fee codes (detailed in Additional file 1). Our
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90 days of surgery (in our data sources the code has a
sensitivity of 97.8% and specificity of 100% for the find-
ing of death) [33].
Primary analyses
We performed all statistical analyses at the Institute for
Clinical Evaluative Sciences using SAS 9.2 (SAS Institute,
Cary, NC, USA). We assessed differences in baseline char-
acteristics between ACEi/ARB users and non-users using
standardized differences. As recommended by others, we
considered a standardized difference of>10% as a mean-
ingful difference between the two groups [34]. To deter-
mine the association between ACEi/ARB use and study
outcomes, we conducted multivariable logistic regression
analyses and estimated adjusted odds ratios (ORs) and
95% confidence intervals (CIs). We interpreted odds ratios
as relative risks (RRs) (appropriate given the incidences
observed) [35]. In the logistic regression analyses, we ad-
justed for the following prespecified baseline characteris-
tics associated with ACEi/ARB use and postoperative AKI
[2,3,6-8,10,11,15,36,37]: age, sex, CKD, coronary artery
disease, congestive heart failure, cerebrovascular disease,
peripheral vascular disease, chronic obstructive pulmonary
disease, chronic liver disease, type of surgery (cardiac, vas-
cular, thoracic, abdominal, retro-peritoneal), era of surgery
(1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007,
2008 to 2010), and use of one or more drugs from the
following medication groups - anti-diabetic medications,
β-blockers, calcium channel blockers, non-potassium
sparing diuretics, and statins. The presence of all of these
characteristics was assessed with database codes (detailed
in Additional file 1).
Additional analyses
Propensity score matching
We derived a propensity score for every patient from all
the potential confounders prespecified in our primary
analysis. The propensity score indicated the likelihood
of receiving a preoperative ACEi/ARB [38,39]. We de-
rived a propensity score matched cohort of ACEi/ARB
users and non-users, matching each ACEi/ARB user to
a non-user on a one to one basis on the following char-
acteristics: age (± 5 years), sex, CKD, and a caliper width
of± 0.2 standard deviation of the propensity score
[3,38,39]. Each non-user could be selected once only.
We assessed differences in baseline characteristics be-
tween matched cohort of ACEi/ARB users and non-
users using standardized differences. To determine the
association between ACEi/ARB use and study out-
comes, we conducted conditional logistic regression
analyses and estimated RRs and 95% CIs. We also calcu-
lated absolute risk reduction in study outcomes with
ACEi/ARB use compared to non-use.
Subgroup analyses
CKD is a strong risk factor for postoperative AKI [7,10].
We performed sub-group analysis to explore whether pre-
existing CKD was an effect modifier of the association be-
tween ACEi/ARB use and study outcomes. Additionally, we
also performed sub-group analyses for congestive heart fail-
ure and diabetes (determined by anti-diabetic medications
prescription). We adjusted for all potential confounders in-
cluded in the primary analyses except the sub-group factor
being tested. A P value< 0.05 for the test of interaction was
considered statistically significant.
Time to event analysis
We performed multivariable Cox-proportional hazards
regression analyses to examine the association between
ACEi/ARB use and study outcomes accounting for the
time to event. We adjusted for all prespecified potential
confounders and estimated the adjusted hazard ratios
(HRs) and 95% CIs.
Results
Baseline characteristics: ACEi/ARB users and non-users
We selected 237,208 adult patients from 118 hospitals in
Ontario, of whom 101,494 (42.8%) were ACEi/ARB users
(Table 1) (selection figure detailed in Additional file 1).
ACEi/ARB users, compared to non-users, were more
likely to be male and have CKD, cerebrovascular disease,
peripheral vascular disease, coronary artery disease, and
congestive heart failure. ACEi/ARB users, compared to
non-users, were more likely to be on anti-diabetic medica-
tions, other anti-hypertensive medications (β-blockers,
calcium channel blockers, and non-potassium sparing di-
uretics), and statins. ACEi/ARB users, compared to non-
users, were more likely to undergo cardiac and vascular
surgeries. Patients having their surgery in more recent
years (2002 to 2010) were more likely to have received
ACEi/ARB prior to surgery compared to prior years (1995
to 2001).
Primary analyses: AKI-D and all-cause mortality
After adjusting for potential confounders, preoperative
ACEi/ARB use was associated with a lower risk of AKI-
D (adjusted RR: 0.83; 95% CI: 0.71 to 0.98) and a lower
risk of all-cause mortality (adjusted RR: 0.91; 95% CI:
0.87 to 0.95) (Table 2; associations with all variables in
the model are presented in Additional file 1).
Additional analyses
Propensity score matched analyses: AKI-D and all-cause
mortality
A total of 67,822 ACEi/ARB users were successfully
matched to 67,822 non-users (Table 1). Baseline character-
istics were well balanced between matched ACEi/ARB
users and non-users (Table 1). Similar to the primary
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Pre-matched cohort Propensity matched cohort
ACEi/ARB users Non-users ACEi/ARB users Non-users
N= 101,494 N= 135,714 N= 67,822 N= 67,822
Demographics
Women 41,034 (40.4%) 60,522 (44.6%) 29,425 (43.4%) 29,425 (43.4%)
Age at index date (years) 74 (70 to 78) 73 (69 to 78) 74 (70 to 78) 74 (70 to 78)
Age groups (years)
66 to 70 30,557 (30.1%) 43,652 (32.2%) 20,098 (29.6%) 20,165 (29.7%)
71 to 75 30,966 (30.5%) 40,782 (30.0%) 20,482 (30.2%) 20,391 (30.1%)
76 to 80 23,898 (23.5%) 29,529 (21.8%) 15,982 (23.6%) 15,779 (23.3%)
81 to 85 11,812 (11.6%) 15,361 (11.3%) 8,101 (11.9%) 8,205 (12.1%)
86 to 90 3,651 (3.6%) 5,294 (3.9%) 2,682 (4.0%) 2,761 (4.1%)
91+ 610 (0.6%) 1,096 (0.8%) 477 (0.7%) 521 (0.8%)
Comorbidities
Chronic kidney disease 7,538 (7.4%)
a 5,027 (3.7%)
a 3,852 (5.7%) 3,852 (5.7%)
Coronary artery disease 67,921 (66.9%)
a 61,137 (45.0%)
a 40,114 (59.1%) 40,346 (59.5%)
Congestive heart failure 22,108 (21.8%)
a 12,413 (9.1%)
a 10,740 (15.8%) 10,317 (15.2%)
Cerebrovascular disease 18,016 (17.8%)
a 17,551 (12.9%)
a 10,970 (16.2%) 11,097 (16.4%)
Peripheral vascular disease 6,490 (6.4%)
a 5,571 (4.1%)
a 3,675 (5.4%) 3,599 (5.3%)
COPD 5,806 (5.7%) 7,121 (5.2%) 3,789 (5.6%) 3,527 (5.2%)
Chronic liver disease 295 (0.3%) 478 (0.4%) 200 (0.3%) 194 (0.3%)
Medications
Oral hypoglycemic 21,267 (21.0%)
a 10,381 (7.6%)
a 8,766 (12.9%) 8,625 (12.7%)
Insulin 6,089 (6.0%)
a 2,381 (1.8%)
a 2,348 (3.5%) 1,937 (2.9%)
Anti-diabetic medication
b 25,041 (24.7%)
a 12,215 (9.0%)
a 10,364 (15.3%) 10,076 (14.9%)
β-blocker 44,835 (44.2%)
a 34,096 (25.1%)
a 24,550 (36.2%) 24,702 (36.4%)
Calcium channel blocker 36,659 (36.1%)
a 32,859 (24.2%)
a 21,630 (31.9%) 22,131 (32.6%)
Diuretic
c 40,345 (39.8%)
a 22,042 (16.2%)
a 19,830 (29.2%) 19,595 (28.9%)
Statin 53,915 (53.1%)
a 31,691 (23.4%)
a 27,348 (40.3%) 26,913 (39.7%)
Surgical characteristics
Type of surgery
Cardiac surgery 40,694 (40.1%)
a 29,475 (21.7%)
a 22,222 (32.8%) 22,380 (33.0%)
Vascular surgery 18,459 (18.2%)
a 18,969 (14.0%)
a 11,509 (17.0%) 11,904 (17.5%)
Thoracic surgery 5,771 (5.7%) 10,177 (7.5%) 4,561 (6.7%) 4,176 (6.2%)
Abdominal surgery 30,471 (30.0%)
a 64,911 (47.8%)
a 24,592 (36.2%) 24,630 (36.3%)
Retro-peritoneal surgery 6,099 (6.0%)
a 12,182 (9.0%)
a 4,938 (7.3%) 4,732 (7.0%)
Era of surgery
1995 to 1998 14,718 (14.5%)
a 45,173 (33.3%)
a 13,278 (19.6%) 13,647 (20.1%)
1999 to 2001 16,900 (16.6%)
a 30,122 (22.2%)
a 13,457 (19.8%) 13,963 (20.6%)
2002 to 2004 20,960 (20.7%)
a 21,992 (16.2%)
a 13,404 (19.8%) 13,194 (19.5%)
2005 to 2007 23,711 (23.4%)
a 19,520 (14.4%)
a 13,625 (20.1%) 13,300 (19.6%)
2008 to 2010 25,205 (24.8%)
a 18,907 (13.9%)
a 14,058 (20.7%) 13,718 (20.2%)
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; COPD: Chronic obstructive pulmonary disease.
Data are presented as number (percent) except age at index date, which is presented as median (interquartile range). Index date is a surgical procedure date or
hospital admission date (if the surgical procedure date is not available).
aRepresents a standardized difference of >10% between ACEi or ARB users and non-users and we considered it as a meaningful difference [34]. Standardized
difference is less sensitive to sample size compared to traditional hypothesis tests and is calculated by examining the difference between the two groups divided
by the pooled standard deviation of the two groups [34].
bAnti-diabetic medication includes oral hypoglycemic and insulin.
cDiuretic include loop diuretic and thiazide diuretic. 3.0% (3,091/101,494) patients were on ACEi and ARB.
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a lower risk of AKI-D (RR: 0.77; 95% CI: 0.65 to 0.92) and
a lower risk of all-cause mortality (RR: 0.93; 95% CI: 0.88
to 0.97) (Table 3). ACEi/ARB use, compared to non-use,
was associated with 0.09% (95% CI: 0.03% to 0.16%) abso-
lute risk reduction in AKI-D and 0.35% (95% CI: 0.12% to
0.57%) absolute risk reduction in all-cause mortality.
Subgroup analyses: AKI-D and all-cause mortality
We found CKD significantly modified the association be-
tween ACEi/ARB use and AKI-D (test of interaction, P
value<0.001). The observed benefit was evident in pa-
tients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to
0.78 and not in those without CKD: adjusted RR: 1.00;
95% CI: 0.81 to 1.24) (Table 4). There was no significant
interaction between ACEi/ARB use and CKD for all-cause
mortality (test of interaction, P value=0.26). We did not
find a significant interaction between ACEi/ARB use and
the outcomes in subgroups of patients defined by the pres-
ence of congestive heart failure and diabetes (Table 4).
Time to event analyses: AKI-D and all-cause mortality
Similar to the primary analyses, preoperative ACEi/ARB
use was associated with a lower risk of AKI-D (adjusted
HR: 0.83; 95% CI: 0.71 to 0.97) and all-cause mortality
(adjusted HR: 0.91; 95% CI: 0.88 to 0.95).
Discussion
Contrary to the results of other studies, in this analysis
preoperative ACEi/ARB use versus non-use was associ-
ated with 17% lower risk of AKI-D and 9% lower risk of
all-cause mortality, when we adjusted for a set of prespe-
cified potential confounders. We found similar results in
the propensity score matched analyses. The association
of preoperative ACEi/ARB use versus non-use on AKI-D
was only evident in patients with CKD.
With respect to mechanism, it is possible that poten-
tial benefits of ACEi/ARB use in surgical settings relates
to angiotensin II inhibition [36,40-42]. Angiotensin II is
a potent vasoconstrictor, which can cause postoperative
AKI (i.e., true tubular injury) by increasing oxidative
stress, endothelial dysfunction, inflammatory response,
and renal vascular resistance, and by reducing renal
blood flow [36,42]. By inhibiting angiotensin II, ACEi/
A R Bu s em a yi n c r e a s et h er i s ko ff u n c t i o n a lA K I( i . e . ,a
drop in GFR) but may paradoxically reduce the risk of
“true AKI” (true tubular injury) [36,40-42]. In this re-
gard, ACEi and ARB may improve renal blood flow and
oxygenation to the renal tubules by vasodilatation of ef-
ferent arterioles and may prevent tubular cell necrosis
during ischemic insults arou n ds u r g e r y[ 1 3 ] .T ow i t ,a
recent analysis from a large multi-center cohort of pa-
tients undergoing cardiac surgery (TRIBE-AKI cohort)
showed that while AKI defined by changes in serum
creatinine, was higher in those that had ACEi or ARB
continued pre-operatively, there was not a concomitant
increase in several biomarkers of kidney injury [43].
While that study may also suffer confounding by indica-
tion, most impressive is that despite greater comorbidi-
ties in patients that continued ACEi/ARB, the kidney
injury biomarkers still were not more elevated, suggest-
i n gs o m ep r o t e c t i v eb e n e f i to ft h e s ea g e n t s[ 4 3 ] .
Table 2 Association between preoperative ACEi/ARB use and outcomes
Outcomes No. of patients with events (percent) Adjusted
a RR
(95% CI) ACEi/ARB users Non-users
(N=101,494) (N=135,714)
AKI-D 438 (0.43%) 372 (0.27%) 0.83 (0.71, 0.98)
All-cause mortality 4,654 (4.59%) 6,435 (4.74%) 0.91 (0.87, 0.95)
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative Risk; CI: Confidence Interval; AKI-D: Acute kidneyi n j u r yt r e a t e dw i t hd i a l y s i s .
Outcomes: (1) Primary outcome: AKI-D (within 14 days of surgery); (2) Secondary outcome: All-cause mortality (within 90 days of surgery).
Relative risk was calculated for preoperative ACEi/ARB use compared to non-use.
aAdjusted for age, sex, chronic kidney disease, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic
obstructive pulmonary disease, chronic liver disease, anti-diabetic agents, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics,
statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010).
Table 3 Propensity score matched cohort: association between preoperative ACEi/ARB use and outcomes
Outcomes No. of patients with events (percent) RR (95% CI) ARR (95% CI)
ACEi/ARB users Non-users
(N=67,822) (N= 67,822)
AKI-D 215 (0.32%) 278 (0.41%) 0.77 (0.65, 0.92) 0.09% (0.03%, 0.16%)
All-cause mortality 3,060 (4.51%) 3,295 (4.86%) 0.93 (0.88, 0.97) 0.35% (0.12%, 0.57%)
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative Risk; CI: Confidence Interval; ARR: Absolute risk reduction; AKI-D:
Acute kidney injury treated with dialysis.
Outcomes: (1) Primary outcome: AKI-D (within 14 days after surgery); (2) Secondary outcome: All-cause mortality (within 90 days after surgery).
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use.
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studies by Benedetto et al.a n dB a r o d k aet al. [40,41]
Benedetto et al. studied 536 patients who underwent car-
diac surgery and observed a lower risk of AKI with pre-
operative ACEi use compared to non-use (adjusted OR:
0.48; 95% CI: 0.23 to 0.77) [41]. The authors presumed the
pathophysiologic benefit of ACEi use stemmed from
the preservation of renal blood flow during surgery [41].
Barodka et al. found similar benefits with preoperative
ACEi/ARB use compared to non-use in 346 patients who
underwent cardiac surgery (adjusted OR: 0.19; 95% CI:
0.04 to 0.84) [40].
Other observational studies by Rady et al. [44],
Ouzounian et al. [37], and Yoo et al. [45], studied 11330,
1647, and 472 cardiac surgery patients, respectively, and
demonstrated no significant association between pre-
operative ACEi/ARB use and AKI. However, all three
studies observed a non-significant trend towards a benefit
with preoperative ACEi/ARB use raising the possibility of
insufficient statistical power to detect the association
[37,44,45].
Miceli et al. performed a propensity score matched
analysis in 9,274 patients who underwent cardiac surgery
and noted a 1.36 fold higher risk of AKI (adjusted OR:
1.36; 95% CI: 1.10 to 1.67) with preoperative ACEi/ARB
use compared to non-use and a two-fold higher risk of
mortality (adjusted OR: 2.00; 95% CI: 1.17 to 3.42) [8].
The authors speculated that the AKI occurred as a result of
a decrease in renal perfusion, mainly due to reduction in
mean arterial pressure along with increased use of vasocon-
strictors [8]. Both Cittanova et al. and Arora et al. also ob-
served an increased risk of AKI with preoperative ACEi
and ARB use, although the study samples were small (249
aortic surgery patients and 1358 cardiac surgery patients,
respectively) [11,46]. Railton et al.s t u d i e dt h eo u t c o m eo f
AKI-D and observed a higher incidence of AKI-D with
ACEi/ARB use compared to non-use in patients who
underwent abdominal aortic aneurysm repair (4.6% vs.
0.8%; P value=0.01) [47]. However, the number of patients
(n=883) and number of events (n=24) were small [47].
Major considerations when comparing our results with
previous studies are the heterogeneous AKI definitions,
type of surgery, and the consideration of preoperative
CKD in statistical analysis. Our primary outcome was
AKI-D, which is the acute renal outcome most important
to patients and their health-care providers [1-3,5]. The
outcome of AKI-D is distinct from AKI defined solely by
acute changes in serum creatinine [48]. The latter is a
Table 4 Influence of chronic kidney disease, congestive heart failure, and diabetes on association between preoperative
ACEi/ARB use and outcomes
Outcomes Presence/absence of comorbid condition Adjusted
a RR (95% CI) P value (test for interaction)
AKI-D CKD Yes 0.62 (0.50, 0.78) <0.001
No 1.00 (0.81, 1.24)
CHF Yes 0.62 (0.45, 0.85) 0.29
No 0.81 (0.65, 1.00)
Diabetes Yes 0.63 (0.43, 0.91) 0.56
No 0.77 (0.63, 0.94)
All-cause mortality CKD Yes 0.86 (0.75, 0.98) 0.26
No 0.91 (0.87, 0.96)
CHF Yes 1.01 (0.91, 1.12) 0.06
No 0.92 (0.86, 0.97)
Diabetes Yes 0.96 (0.86, 1.09) 0.34
No 0.93 (0.88, 0.99)
ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative risk; CI: Confidence interval; AKI-D: Acute kidney injury treated with
dialysis; CKD: Chronic kidney disease; CHF: Congestive heart failure.
Outcomes: (1) Primary outcome: AKI-D (within 14 days after surgery); (2) Secondary outcome: All-cause mortality (within 90 days after surgery).
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use.
aCKD sub-group analyses: adjusted for age, sex, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic
obstructive pulmonary disease, chronic liver disease, anti-diabetic agents, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics,
statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008
to 2010).
aCHF sub-group analyses: adjusted for age, sex, coronary artery disease, chronic kidney disease, cerebrovascular disease, peripheral vascular disease, chronic
obstructive pulmonary disease, chronic liver disease, anti-diabetic agents, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics,
statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008
to 2010).
aDiabetes sub-group analyses: adjusted for age, sex, coronary artery disease, chronic kidney disease, congestive heart failure, cerebrovascular disease, peripheral
vascular disease, chronic obstructive pulmonary disease, chronic liver disease, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics,
statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008
to 2010).
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the ACEi or ARB setting (i.e. use of these medications in
outpatient settings may increase serum creatinine concen-
tration despite evidence that the drugs prevent progres-
sion to ESRD requiring chronic maintenance dialysis)
[11,49,50].
CKD is considered to be the most important risk fac-
tor for AKI [7,10]. However, the majority of previous
studies did not account for CKD in their analyses
[8,11,37,40,41,44-46]. In this study, we observed an associ-
ation of less AKI-D with preoperative ACEi/ARB use com-
pared to non-use only in patients with preoperative CKD .
One concern interpreting this result is that CKD patients
not receiving preoperative ACEi/ARB may represent an
advanced disease population where ACEi/ARB might have
been stopped due to the risk of early onset chronic main-
tenance dialysis [51]. Another concern is that we identified
CKD patients using database codes which have limited
validity. These codes underestimate CKD prevalence may
have impacted the study results. Moreover, this prevented
us from examining CKD stages according to preferred
glomerular filteration rate (eGFR) categories [30,52].
Study strengths and limitations
Our study has several strengths. To the best of our
knowledge, this is the largest study to describe the asso-
ciation between preoperative ACEi/ARB use and AKI-D
(over 230,000 patients from 118 hospitals). We included
both cardiac and non-cardiac major surgeries. Unlike
other studies, the large number of events of AKI-D (810
events) reduced concerns about statistical overfitting
[53]. Given there is <1% yearly emigration from Ontario,
the loss to follow up was minimal. Finally, the informa-
tion available within the large Ontario health care data-
bases reflects routine clinical practice and may be less
prone to participation biases that can arise in other types
of studies [3,19-23].
There are several limitations to our study. Due to pos-
sible difference in underlying mechanism for the risk of
postoperative acute dialysis in emergent surgeries com-
pared to elective surgeries, we excluded emergent surger-
ies from our analyses. In an emergency situation it is also
difficult to manipulate pre-operative medication use.
However, exclusion of emergency surgeries may have re-
duced the generalizability of the study results. We could
not determine medication compliance from evidence of a
dispensed prescription for ACEi, ARB, or other medica-
tions in our data sources. Our study was limited by the ab-
sence of key information on perioperative ACEi/ARB use
particularly whether it was held prior to surgery and if so
when it was held, and when it was restarted after surgery.
Important information such as preoperative and intraop-
erative blood pressure was also not available. These are
key elements to guide the optimal and safe use of ACEi/
ARB use in the perioperative period, including regimens
to be tested in large randomized controlled trials (RCTs).
We were also not able to adjust for variables unavailable
in our data sources such as body mass index, preoperative
proteinuria, non-prescription medication use and in hos-
pital medication use. Another limitation with our data
sources is the accuracy of codes for patient related health
information. In attempt to limit these concerns, we did
use database codes supported by validation studies when-
ever possible [25-32].
Study implications and future directions
Our study results support the need for RCTs in this set-
ting, to test a regimen of perioperative ACEi/ARB selected
for optimal efficacy and safety. Given the low incidence of
acute dialysis (about 0.45% in all types of major surgery
[1-3]), a very large trial (over 150,000 patients) would be
needed to examine a meaningful difference with this as a
primary outcome. Such a trial is unlikely to occur. How-
ever, if we consider a primary outcome of 90-day all-cause
mortality (4.67% of patients in our study), the sample size
is tenable at about 15,000 patients. The sample size could
be further reduced if there is a rationale to consider a
composite of clinically important events including peri-
operative cardiac events. Enrolling a large number of pa-
tients with CKD may be prudent, as in the current study
the signal of benefit for AKI-D was strongest in this group
of patients. Given the large number of surgeries compli-
cated by AKI-D worldwide each year, we propose that
such RCTs should be undertaken.
Conclusions
In this cohort study, preoperative ACEi/ARB use versus
non-use was associated with a lower risk of AKI-D, and the
association was primarily evident in patients with CKD.
Large, multi-centre randomized trials are needed to inform
optimal ACEi/ARB use in the peri-operative setting.
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